Happy New Year to everyone, including all our valued customers, patients, partners, and employees. We wish you a healthy and safe 2023.

RT @GeneDx: Last week we exhibited at #HotTopicsNeo2022, showcasing our research and collaboration efforts, the benefits of #exome sequenci….

A recent study we worked on with @UW and @seattlechildren's Hospital shows the clear benefits of rapid whole #genome sequencing for diagnosing critically ill #newborns in the #NICU. Learn more about the results of the research:

RT @GeneDx: #Exome sequencing is now recognized as a first-tier #genetic testing option for unexplained #epilepsy by the @GeneticCouns and….

We have announced new research highlighting the importance of rapid #exome sequencing for #mitochondrial diseases in the #NICU. Our study underscores the opportunity to improve health outcomes for infants with early medical intervention. Learn more:

RT @GeneDx: Attending #HotTopicsNeo2022? Join our sponsored lunch symposium to learn about rapid #genome sequencing and discuss clinical ap….

RT @GeneDx: We stand with @AmEpilepsySoc in supporting @GeneticCouns’ new guidelines recommending #exome sequencing as a first-tier test fo….

RT @GeneDx: Attending #HotTopicsNeo2022? Stop by booth #240 to learn about our #genetic testing offerings. Also explore how we support prov….

RT @GeneDx: We’re excited to exhibit at #AES2022 in Nashville, TN from 12/2 - 12/6. Join us on Friday, 12/2 from 9am-12pm CT at the ”Geneti….

What are the goals of the GUARDIAN study? Learn how we’ll impact the lives of 100k #newborns in #NewYork and why we were selected to provide whole #genome sequencing & interpretation services for the landmark study:

On this #Thanksgiving, we’d like to sincerely thank our patients, customers, and partners for their support and for being at the core of our mission to deliver personalized, actionable #health insights. We hope you have a joyous holiday. Happy Thanksgiving!

RT @GeneDx: Supporting organizations like @DDX3X is an important part of our work, and we were proud to attend their annual scientific conf….

.@LabPulse1 featured our recent collaboration with @MassGeneralNews on new research demonstrating #genome & #exome sequencing deliver more diagnostic certainty than multi-gene panels. Read more:

Sema4 today announced 3Q 2022 business highlights and financial results, and a new strategic direction that the company believes will enable it to scale to profitability. Read more: $SMFR

Happy #GeneticCounselorAwareness Day! We celebrate all #GeneticCounselors, their valuable skills & the critical role they play in #patients’ lives. Learn how our GCs help patients & clinicians understand the complexity of #genetic information: #GCchat

What is the driving force behind the groundbreaking GUARDIAN study? Read our recent Q&A with Chief Medical Officer of GeneDx at Sema4, @paul_kruszka, to learn how our whole #genome sequencing will impact the lives of 100k+ #newborns in #NewYorkCity:

We’re presenting new research at #NSGC22 next week. Meet us at booth #417 to learn about our research, offerings, & more. Also visit our website to explore how we support the #patient journey through our whole #genome sequencing & whole #exome sequencing:

November is #NativeAmericanHeritageMonth. We recognize and honor the culture and contributions of Native Americans, Alaska Natives, Native Hawaiians, and all indigenous people this month and beyond. #NAHM

Sema4 will release financial results for the third quarter of 2022 before the market opens on Monday, November 14th. On the same day, we will host a conference call to discuss financial and operating results at 8:30 a.m. ET. Read more:

.@lifesciencesint recently interviewed Dr. @paul_kruszka, CMO of GeneDx at Sema4, on our role in the GUARDIAN study, the benefits of implementing whole #genome sequencing as the standard of care, & the need for this scientific advancement in #healthcare: